Abstract Purpose of Review Apoptosis is a major mechanism of cancer cell death. Thus,
evasion of apoptosis results in therapy resistance. Here, we review apoptosis modulators in …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Cancer vaccines, which are designed to amplify tumour-specific T cell responses through
active immunization, have long been envisioned as a key tool of effective cancer …

Research on tumor immunotherapy has made tremendous progress in the past decades,
with numerous studies entering the clinical evaluation. The cancer vaccine is considered a …

In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …

Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the
goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor found
in the central nervous system. Currently, standard treatments in the clinic include maximal …

Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery
more than two decades ago, the use of survivin as a target for cancer therapeutics has …

PURPOSE Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ)
chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) …

Glioblastoma (GBM) is the most common malignant brain tumor. Despite multimodality
treatment with surgical resection, radiation therapy, chemotherapy, and tumor treating fields …